| Literature DB >> 30511787 |
Jørn Eivind Tungen1, Lisa Gerstmann1,2, Anders Vik1, Roberta De Matteis3, Romain Alexandre Colas3, Jesmond Dalli3, Nan Chiang4, Charles Nicholas Serhan4, Markus Kalesse2, Trond Vidar Hansen1.
Abstract
New drugs that can resolve inflammation without immunosuppressive effects are at the medicinal chemistry frontier. Pro-resolving endogenously formed small molecules, that is, the resolvins, are excellent candidates displaying such bioactions. The first total synthesis of the specialized pro-resolving mediator RvD1n-3 DPA has been achieved using the underutilized sp3 -sp3 Negishi cross coupling reaction and an alkyne hydrosilylation-protodesilylation protocol. Biological evaluations revealed that this novel mediator displays low nanomolar pro-resolving properties and potently activates the human DRV1/GPR32 receptor. As such, this endogenous natural product is a lead compound for the development of novel immunoresolvents.Entities:
Keywords: Karstedt's catalyst; natural products; sp3-sp3 cross-coupling; specialized pro-resolving mediators; total synthesis
Mesh:
Substances:
Year: 2018 PMID: 30511787 PMCID: PMC6368681 DOI: 10.1002/chem.201806029
Source DB: PubMed Journal: Chemistry ISSN: 0947-6539 Impact factor: 5.236